Clinical Trials
2
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2013
Active, not recruiting
1
50.0%
Recruiting
1
50.0%
No approval data available
- Preliminary Phase 1 data show uTREAT® achieves high tumor uptake and retention with a therapeutically relevant radiation dose while sparing healthy organs in glioblastoma patients. - The super-selective intra-arterial cerebral injection (super-SIACI) with mannitol-mediated blood-brain barrier opening was demonstrated to be feasible and safe. - Curasight's CEO Ulrich Krasilnikoff expressed confidence in advancing the program, calling the approach a potentially game-changing radioligand therapy for glioblastoma. - Glioblastoma carries a dire prognosis with approximately 50% of patients dying within 14 months and only 5% surviving five years, underscoring the urgent unmet need.
- Curasight A/S has submitted a Clinical Trial Application to the European Medicines Agency for a Phase 1 trial of uTREAT, a targeted radiopharmaceutical therapy for glioblastoma patients. - The therapy targets the uPAR receptor, with recent Phase II data showing 94% of Grade 4 gliomas were uPAR-positive, supporting the treatment's potential in this aggressive brain cancer. - Glioblastoma affects approximately 30,000 patients annually in the US and EU, with a devastating prognosis where only 5% of patients survive five years after diagnosis. - The company has partnered with Premier Research as the contract research organization to conduct the international Phase 1 trial, with first patient dosing expected in the second half of 2025.
- A Phase II trial of uPAR-PET imaging in glioma patients demonstrates its potential as a prognostic tool for assessing disease progression and overall survival. - The study found that 94% of grade 4 gliomas (glioblastomas) were uPAR-PET positive, indicating high uPAR expression in aggressive tumors. - High uPAR expression, as detected by uPAR-PET, was significantly associated with worse overall survival (OS) and progression-free survival (PFS), with hazard ratios of 14.3 and 26.5, respectively. - These findings suggest that uPAR-PET could help identify candidates for future uPAR-targeted radioligand therapy, potentially improving treatment strategies for brain cancer.
